Tigecycline, a semisynthetic derivative of minocycline, has a broad spectrum of activity against both gram positive and gram negative multidrug resistant bacteria. The drug acts on 30S ribosomal subunit and inhibits protein synthesis. Since the drug has excellent tissue distribution, it is very useful for treatment of skin infections, intra-abdominal infections and pneumonia. Side effects of the drug are usually mild. The common side effects include nausea and vomiting. The exact mechanism of resistance remains unclear. However, resistance mediated by enhanced expression of resistance nodulation cell division (RND) type efflux pumps is one of the most frequently reported mechanisms. Resistance has been observed worldwide. However, the rate...
SummaryBackgroundThis analysis from the global Tigecycline Evaluation and Surveillance Trial (T.E.S....
SummaryBackgroundThis analysis from the global Tigecycline Evaluation and Surveillance Trial (T.E.S....
Tigecycline is the first glycylcycline to be launched and is one of the very few new antimicrobials ...
Tigecycline is unique glycylcycline class of semisynthetic antimicrobial agents developed for the tr...
Tigecycline is unique glycylcycline class of semisynthetic antimicrobial agents developed for the tr...
Tigecycline is unique glycylcycline class of semisynthetic antimicrobial agents developed for the tr...
Tigecycline is a semisynthetic analogue of earlier tetracyclines and represents the first member of ...
Abstract: This paper reviews the antimicrobial profile and available clinical data for the first mem...
The increasing antimicrobial resistance found in the many clinically important species of bacteria t...
New antimicrobial agents are urgently needed for clinical use due to the increasing prevalence and s...
Tigecycline is the first of a new class of antibiotics, the glycylcyclines, with properties which ca...
Tigecycline, a glycylcycline related to the tetracycline class of antibiotics, represents a new opti...
Tigecycline is the first of a new class of antibiotics, the glycylcyclines, with properties which ca...
Tigecycline is a novel glycylcycline that exhibits broad-spectrum antibacterial activity against a w...
ABSTRACTThe incidence of nosocomial disease caused by Gram-negative pathogens is increasing, and inf...
SummaryBackgroundThis analysis from the global Tigecycline Evaluation and Surveillance Trial (T.E.S....
SummaryBackgroundThis analysis from the global Tigecycline Evaluation and Surveillance Trial (T.E.S....
Tigecycline is the first glycylcycline to be launched and is one of the very few new antimicrobials ...
Tigecycline is unique glycylcycline class of semisynthetic antimicrobial agents developed for the tr...
Tigecycline is unique glycylcycline class of semisynthetic antimicrobial agents developed for the tr...
Tigecycline is unique glycylcycline class of semisynthetic antimicrobial agents developed for the tr...
Tigecycline is a semisynthetic analogue of earlier tetracyclines and represents the first member of ...
Abstract: This paper reviews the antimicrobial profile and available clinical data for the first mem...
The increasing antimicrobial resistance found in the many clinically important species of bacteria t...
New antimicrobial agents are urgently needed for clinical use due to the increasing prevalence and s...
Tigecycline is the first of a new class of antibiotics, the glycylcyclines, with properties which ca...
Tigecycline, a glycylcycline related to the tetracycline class of antibiotics, represents a new opti...
Tigecycline is the first of a new class of antibiotics, the glycylcyclines, with properties which ca...
Tigecycline is a novel glycylcycline that exhibits broad-spectrum antibacterial activity against a w...
ABSTRACTThe incidence of nosocomial disease caused by Gram-negative pathogens is increasing, and inf...
SummaryBackgroundThis analysis from the global Tigecycline Evaluation and Surveillance Trial (T.E.S....
SummaryBackgroundThis analysis from the global Tigecycline Evaluation and Surveillance Trial (T.E.S....
Tigecycline is the first glycylcycline to be launched and is one of the very few new antimicrobials ...